Mercanti Leonardo, Sindaco Maria, Mazzone Mariangela, Di Marcantonio Maria Carmela, Piscione Mariagrazia, Muraro Raffaella, Mincione Gabriella
Department of Innovative Technologies in Medicine & Dentistry, University "G. d'Annunzio" of Chieti-Pescara, 66100 Chieti, Italy.
Campus Bio-Medico University of Rome, 00128 Roma, Italy.
Cancers (Basel). 2023 May 26;15(11):2923. doi: 10.3390/cancers15112923.
Pancreatic ductal adenocarcinoma (PDAC) is among the leading causes of death by cancer in the world. What makes this pathological condition particularly lethal is a combination of clinical and molecular heterogeneity, lack of early diagnostic indexes, and underwhelming results from current therapeutic protocols. A major cause of PDAC chemoresistance seems to lie in the ability of cancer cells to spread out and fill the pancreatic parenchyma, exchanging nutrients, substrates, and even genetic material with cells from the surrounding tumor microenvironment (TME). Several components can be found in the TME ultrastructure, including collagen fibers, cancer-associated fibroblasts, macrophages, neutrophils, mast cells, and lymphocytes. Cross-talk between PDAC and TME cells results in the latter being converted into cancer-favoring phenotypes; this behavior could be compared to an influencer guiding followers into supporting his activity. Moreover, TME could be a potential target for some of the newest therapeutic strategies; these include the use of pegvorhyaluronidase-α and CAR-T lymphocytes against HER2, FAP, CEA, MLSN, PSCA, and CD133. Other experimental therapy options are being currently studied, aiming to interfere with the KRAS pathway, DNA-repairing proteins, and apoptosis resistance in PDAC cells. Hopefully these new approaches will grant better clinical outcomes in future patients.
胰腺导管腺癌(PDAC)是全球癌症死亡的主要原因之一。导致这种病理状况特别致命的原因是临床和分子异质性、缺乏早期诊断指标以及当前治疗方案效果不佳。PDAC化疗耐药的一个主要原因似乎在于癌细胞能够扩散并填充胰腺实质,与周围肿瘤微环境(TME)中的细胞交换营养物质、底物甚至遗传物质。在TME超微结构中可以发现几种成分,包括胶原纤维、癌症相关成纤维细胞、巨噬细胞、中性粒细胞、肥大细胞和淋巴细胞。PDAC与TME细胞之间的相互作用导致后者转变为有利于癌症的表型;这种行为可以比作有影响力的人引导追随者支持他的活动。此外,TME可能是一些最新治疗策略的潜在靶点;这些策略包括使用聚乙二醇化透明质酸酶-α和针对HER2、FAP、CEA、MLSN、PSCA和CD133的嵌合抗原受体T淋巴细胞(CAR-T)。目前正在研究其他实验性治疗方案,旨在干扰PDAC细胞中的KRAS途径、DNA修复蛋白和抗凋亡能力。希望这些新方法能为未来的患者带来更好的临床结果。